General
Preferred name
PAVINETANT
Synonyms
MLE-4901 ()
AZD4901 ()
AZD2624 ()
AZD-2624 ()
AZ12472520 ()
AZ-12472520 ()
AZ4901 ()
AZ124752520 ()
MLE4901 ()
Azd 4901 ()
AZD-4901 ()
Azd 2624 ()
P&D ID
PD051936
CAS
941690-55-7
Tags
available
drug candidate
Drug indication
Schizophrenia
Multiple sclerosis
polycystic ovary syndrome
.
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION AZD2624 is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AZ as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase II study for the latter indication was reported in April 2017 . A total of eight analogues are disclosed in the AZ composition of matter filing ,
DESCRIPTION Pavinetant (MLE-4901) is a neurokinin-3 receptor (NK3R) antagonist.
PRICE 256
DESCRIPTION Pavinetant (AZD2624) is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AstraZeneca as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase 2 study for the latter indication was reported in April 2017 . A total of eight analogues are disclosed in the AstraZeneca composition of matter filing , (GtoPdb)
DESCRIPTION Pavinetant is a selective neurokinin-3 (NK3) receptor antagonist under the development of hot flashes, polycystic ovary syndrome (PCOS) and schizophrenia treatment. (BOC Sciences Bioactive Compounds)
DESCRIPTION Pavinetant (MLE-4901) is an orally available neurokinin-3 receptor (NK3R) antagonist used to improve menopausal symptoms. (TargetMol Bioactive Compound Library)
Compound Sets
10
BOC Sciences Bioactive Compounds
azd2624-cas-941690-55-7-item-284138
Cayman Chemical Bioactives
23587
ChEMBL Drugs
CHEMBL3545233
Drug Repurposing Hub
DrugBank
DB11692
DrugMAP
DMZLGQV
Guide to Pharmacology
5775
MedChem Express Bioactive Compound Library
HY-14432
ReFrame library
TargetMol Bioactive Compound Library
T16114
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
459.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
4
cLogP
5.15
TPSA
88.16
Fraction CSP3
0.15
Chiral centers
1.0
Largest ring
6.0
QED
0.4
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
NK3
Neurokinin Receptor
MOA
neurokinin receptor antagonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Source data